Eli Lilly and Company is an American global pharmaceutical company Recreating Drug Discovery for the 21st Century. What does this quote from Lilly’s CEO mean for Lilly’s strategy: “The challenge for us as an industry, as a company, is to move from a blockbuster model to a targeted model… . We need a better value proposition than today.” – Sydney Taurel, CEO, Eli Lilly (The New York Times, July 3, 2005) What is personalized medicine?
What capabilities does Lilly have now and what capabilities must it build to have a targeted therapeutics strategy?
What functional areas of Lilly will house these capabilities?
Where will challenges to the new strategy come from?